Medline’s new agreement to deploy Symbotic (SYM) warehouse automation in its U.S. distribution network introduces the company’s AI powered system to healthcare logistics, giving investors a fresh data point on cross industry adoption.

At a share price of US$63.17, Symbotic’s recent Medline agreement sits alongside a 1 month share price return of 26.04% and a 1 year total shareholder return of 221.97%, suggesting momentum has strengthened again after weaker year to date performance.

If warehouse automation catching healthcare’s attention has you thinking bigger, now is a good time to scan the market with our robotics and automation stock screener, including 34 robotics and automation stocks.

With Symbotic trading near analysts’ price target and showing strong recent returns, the key question for you is whether the Medline agreement and cross industry traction leave upside on the table, or whether markets are already pricing in future growth.

Most Popular Narrative: 1% Undervalued

With Symbotic’s fair value estimate at $64.05 versus the last close at $63.17, the most followed narrative is pricing in only a modest upside, making the assumptions behind that view especially important.

The acceleration of global e-commerce adoption and the resulting push for retailers and wholesalers to overtake legacy distribution models with automation is fueling strong demand for Symbotic's advanced warehouse systems, as evidenced by their record $22.4b backlog and expanding inbound pipeline, and this supports long-term revenue growth.

Curious what justifies that fair value only slightly above today’s price? The narrative leans on rapid earnings growth, higher margins, and a richer future multiple. The exact mix of those inputs may surprise you.

Result: Fair Value of $64.05 (ABOUT RIGHT)

However, there are still real pressure points, including Walmart concentration and deployment delays during the next generation storage upgrade, that could easily put this fair value story to the test.

Another View: Higher Bar on Cash Flows

The fair value narrative paints Symbotic as only 1% undervalued around $64.05, but the SWS DCF model tells a tougher story, with an estimate of $47.49 against the current $63.17 price. This implies the shares screen as expensive on future cash flows. Which lens do you trust more for the long haul?

Next Steps

Seeing mixed signals on value and growth here? Act while the details are fresh in your mind and weigh both sides for yourself through the 2 key rewards and 1 important warning sign

Ready to Find Your Next Idea?

Symbotic’s story is just one angle, and you do not want to miss other opportunities that fit different goals, risk levels, and income needs across the market.

• Target potential upside with companies that look mispriced on quality and value by scanning through 60 high quality undervalued stocks.
• Strengthen the foundation of your portfolio by focusing on companies highlighted in the solid balance sheet and fundamentals stocks screener (41 results).
• Build a stream of potential income plays by reviewing yield focused opportunities inside the 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.